Allison S Dobry1, Charles P Quesenberry2, G Thomas Ray2, Jamie L Geier3, Maryam M Asgari4. 1. Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Population Medicine, Harvard Medical School, Boston, Massachusetts. 2. Division of Research, Kaiser Permanente Northern California, Oakland, California. 3. Pfizer Inc, New York, New York. 4. Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Population Medicine, Harvard Medical School, Boston, Massachusetts; Division of Research, Kaiser Permanente Northern California, Oakland, California.
Abstract
BACKGROUND: Biologic therapy is effective for treatment of moderate-to-severe psoriasis but may be associated with an increased risk for serious infection. OBJECTIVE: To estimate the serious infection rate among patients with psoriasis treated with biologic as compared with nonbiologic systemic agents within a community-based health care delivery setting. METHODS: We identified 5889 adult Kaiser Permanente Northern California health plan members with psoriasis who had ever been treated with systemic therapies and calculated the incidence rates and 95% confidence intervals (CIs) for serious infections over 29,717 person-years of follow-up. Adjusted hazard ratios (aHRs) were calculated using Cox regression. RESULTS: Adjusting for age, sex, race or ethnicity, and comorbidities revealed a significantly increased risk for overall serious infection among patients treated with biologics as compared with those treated with nonbiologics (aHR, 1.31; 95% CI, 1.02-1.68). More specifically, there was a significantly elevated risk for skin and soft tissue infection (aHR, 1.75; 95% CI, 1.19-2.56) and meningitis (aHR, 9.22; 95% CI, 1.77-48.10) during periods of active biologic use. LIMITATIONS: Risk associated with individual drugs was not examined. CONCLUSION: We found an increased rate of skin and soft tissue infections among patients with psoriasis treated with biologic agents. There also was a signal suggesting increased risk for meningitis. Clinicians should be aware of these potential adverse events when prescribing biologic agents.
BACKGROUND: Biologic therapy is effective for treatment of moderate-to-severe psoriasis but may be associated with an increased risk for serious infection. OBJECTIVE: To estimate the serious infection rate among patients with psoriasis treated with biologic as compared with nonbiologic systemic agents within a community-based health care delivery setting. METHODS: We identified 5889 adult Kaiser Permanente Northern California health plan members with psoriasis who had ever been treated with systemic therapies and calculated the incidence rates and 95% confidence intervals (CIs) for serious infections over 29,717 person-years of follow-up. Adjusted hazard ratios (aHRs) were calculated using Cox regression. RESULTS: Adjusting for age, sex, race or ethnicity, and comorbidities revealed a significantly increased risk for overall serious infection among patients treated with biologics as compared with those treated with nonbiologics (aHR, 1.31; 95% CI, 1.02-1.68). More specifically, there was a significantly elevated risk for skin and soft tissue infection (aHR, 1.75; 95% CI, 1.19-2.56) and meningitis (aHR, 9.22; 95% CI, 1.77-48.10) during periods of active biologic use. LIMITATIONS: Risk associated with individual drugs was not examined. CONCLUSION: We found an increased rate of skin and soft tissue infections among patients with psoriasis treated with biologic agents. There also was a signal suggesting increased risk for meningitis. Clinicians should be aware of these potential adverse events when prescribing biologic agents.
Authors: Craig Leonardi; Kim Papp; Bruce Strober; Kristian Reich; Akihiko Asahina; Yihua Gu; Joseph Beason; Stephen Rozzo; Stephen Tyring Journal: Am J Clin Dermatol Date: 2011-10-01 Impact factor: 7.403
Authors: Howard H Moffet; Nancy Adler; Dean Schillinger; Ameena T Ahmed; Barbara Laraia; Joe V Selby; Romain Neugebauer; Jennifer Y Liu; Melissa M Parker; Margaret Warton; Andrew J Karter Journal: Int J Epidemiol Date: 2008-03-07 Impact factor: 7.196
Authors: Joel M Gelfand; Joy Wan; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Michael B Stierstorfer; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Andrea B Troxel; Daniel B Shin; Jane M Steinemann; Jennifer Goldfarb; Howa Yeung; Abby S Van Voorhees Journal: Arch Dermatol Date: 2012-04
Authors: N H Shear; M Hartmann; M Toledo-Bahena; A Katsambas; L Connors; Q Chang; R Yao; K Nograles; Z Popmihajlov Journal: Br J Dermatol Date: 2014-08-13 Impact factor: 9.302
Authors: Alan Menter; Steven R Feldman; Gerald D Weinstein; Kim Papp; Robert Evans; Cynthia Guzzo; Shu Li; Lisa T Dooley; Cynthia Arnold; Alice B Gottlieb Journal: J Am Acad Dermatol Date: 2006-09-06 Impact factor: 11.527
Authors: Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282
Authors: Xintong Li; Kathleen M Andersen; Hsien-Yen Chang; Jeffrey R Curtis; G Caleb Alexander Journal: Ann Rheum Dis Date: 2019-10-31 Impact factor: 19.103
Authors: Patrick J McCullough; William P McCullough; Douglas Lehrer; Jeffrey B Travers; Steven J Repas Journal: Nutrients Date: 2021-04-29 Impact factor: 5.717
Authors: Lawrence F Eichenfield; Thomas Bieber; Lisa A Beck; Eric L Simpson; Diamant Thaçi; Marjolein de Bruin-Weller; Mette Deleuran; Jonathan I Silverberg; Carlos Ferrandiz; Regina Fölster-Holst; Zhen Chen; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; George D Yancopoulos; Marius Ardeleanu Journal: Am J Clin Dermatol Date: 2019-06 Impact factor: 7.403